These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 17095339

  • 1. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study.
    Qaqundah PY, Sugerman RW, Ceruti E, Maspero JF, Kleha JF, Scott CA, Wu W, Mehta R, Crim C.
    J Pediatr; 2006 Nov; 149(5):663-670. PubMed ID: 17095339
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P.
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [Abstract] [Full Text] [Related]

  • 3. Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids.
    Lumry WR, Conway MM, LaForce CF, Pearlman DS, Scott CA, Herje NE, Wu WW, Crim C.
    Ann Allergy Asthma Immunol; 2006 Jan; 96(1):51-9. PubMed ID: 16440533
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study.
    Wasserman RL, Baker JW, Kim KT, Blake KV, Scott CA, Wu W, Faris MA, Crim C.
    Ann Allergy Asthma Immunol; 2006 Jun; 96(6):808-18. PubMed ID: 16802768
    [Abstract] [Full Text] [Related]

  • 5. Systemic exposure and urinary cortisol effects of fluticasone propionate formulated with hydrofluoroalkane in 4- to 11-year-olds with asthma.
    Kim KT, Milgrom H, Yoon YK, Levy AL, Matz P, Welch MJ, Cahn A, Collins DA, Kathman S, Mehta R, Su SF, Kunka RL.
    J Clin Pharmacol; 2008 Jan; 48(1):108-16. PubMed ID: 18094223
    [Abstract] [Full Text] [Related]

  • 6. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM, Boulet LP, Follows RM.
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment.
    Nelson HS, Wolfe JD, Gross G, Greos LS, Baitinger L, Scott C, Dorinsky P.
    Ann Allergy Asthma Immunol; 2003 Sep; 91(3):263-9. PubMed ID: 14533658
    [Abstract] [Full Text] [Related]

  • 8. Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma.
    Pinnas JL, Noonan MJ, Weinstein SF, Chervinsky P, Scott CA, Herje NE, Wu W, Crim C.
    J Asthma; 2005 Dec; 42(10):865-71. PubMed ID: 16393726
    [Abstract] [Full Text] [Related]

  • 9. Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life.
    Edin HM, Andersen LB, Schoaf L, Scott-Wilson CA, Ho SY, Ortega HG.
    Ann Allergy Asthma Immunol; 2009 Apr; 102(4):323-7. PubMed ID: 19441604
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group.
    Tonnel AB, Bons J, Legendre M, Prud'Homme A, Bugnas B, Evano-Celli I, Stuart AM.
    Respir Med; 2000 Jun; 94 Suppl B():S29-34. PubMed ID: 10919683
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of salmeterol/fluticasone propionate versus fluticasone propionate in asthma patients: a randomized, double-blind study.
    Lee YS, Lin HC, Huang CD, Lee KY, Liu CY, Yu CT, Wang CH, Kuo HP.
    Chang Gung Med J; 2011 Jun; 34(4):382-94. PubMed ID: 21880193
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma.
    Pearlman DS, Peden D, Condemi JJ, Weinstein S, White M, Baitinger L, Scott C, Ho SY, House K, Dorinsky P.
    J Asthma; 2004 Jun; 41(8):797-806. PubMed ID: 15641629
    [Abstract] [Full Text] [Related]

  • 13. Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma.
    Shapiro GS, Klinger NM, Ekholm BP, Colice GL.
    J Asthma; 2000 Dec; 37(8):667-75. PubMed ID: 11192231
    [Abstract] [Full Text] [Related]

  • 14. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL, Boulet LP, Keith PK, Scott-Wilson CA, House KW, Dorinsky PM.
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids.
    You-Ning L, Humphries M, Du X, Wang L, Jiang J.
    Int J Clin Pract; 2005 Jul; 59(7):754-9. PubMed ID: 15963199
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT, Mehta R, Chan RH, Despa SX, Louey MD.
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [Abstract] [Full Text] [Related]

  • 17. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma.
    Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, Crim C.
    J Pediatr; 2005 Aug; 147(2):213-20. PubMed ID: 16126052
    [Abstract] [Full Text] [Related]

  • 18. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.
    Galant SP, van Bavel J, Finn A, Gross G, Pleskow W, Brown A, Hamedani AG, Harding SM.
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):273-80. PubMed ID: 10094218
    [Abstract] [Full Text] [Related]

  • 19. Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma.
    Sher LD, Yiu G, Sakov A, Liu S, Caracta CF.
    Allergy Asthma Proc; 2017 Sep 21; 38(5):343-353. PubMed ID: 28639542
    [Abstract] [Full Text] [Related]

  • 20. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group.
    Perruchoud AP, Lundback B, Yigla M, Sykes AP.
    Respir Med; 2000 Jun 21; 94 Suppl B():S35-41. PubMed ID: 10919684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.